241 related articles for article (PubMed ID: 20099988)
21. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
Shadle CR; Lee Y; Majumdar AK; Petty KJ; Gargano C; Bradstreet TE; Evans JK; Blum RA
J Clin Pharmacol; 2004 Mar; 44(3):215-23. PubMed ID: 14973304
[TBL] [Abstract][Full Text] [Related]
23. Effect of glycyrrhizin on the activity of CYP3A enzyme in humans.
Tu JH; He YJ; Chen Y; Fan L; Zhang W; Tan ZR; Huang YF; Guo D; Hu DL; Wang D; Hong-Hao Zhou
Eur J Clin Pharmacol; 2010 Aug; 66(8):805-810. PubMed ID: 20393696
[TBL] [Abstract][Full Text] [Related]
24. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
25. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
Iwamoto M; Kassahun K; Troyer MD; Hanley WD; Lu P; Rhoton A; Petry AS; Ghosh K; Mangin E; DeNoia EP; Wenning LA; Stone JA; Gottesdiener KM; Wagner JA
J Clin Pharmacol; 2008 Feb; 48(2):209-14. PubMed ID: 18077730
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
[TBL] [Abstract][Full Text] [Related]
27. Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.
Shaw JP; Cheong J; Goldberg MR; Kitt MM
Antimicrob Agents Chemother; 2010 Aug; 54(8):3365-71. PubMed ID: 20516282
[TBL] [Abstract][Full Text] [Related]
28. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
Malati CY; Robertson SM; Hunt JD; Chairez C; Alfaro RM; Kovacs JA; Penzak SR
J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
[TBL] [Abstract][Full Text] [Related]
29. Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.
Abdlekawy KS; Donia AM; Elbarbry F
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):397-405. PubMed ID: 27294349
[TBL] [Abstract][Full Text] [Related]
30. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
33. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
34. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.
Ma JD; Nafziger AN; Rhodes G; Liu S; Gartung AM; Bertino JS
J Clin Pharmacol; 2006 Jan; 46(1):103-8. PubMed ID: 16397289
[TBL] [Abstract][Full Text] [Related]
35. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
Shaw JP; Seroogy J; Kaniga K; Higgins DL; Kitt M; Barriere S
Antimicrob Agents Chemother; 2005 Jan; 49(1):195-201. PubMed ID: 15616296
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
38. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Ermer J; Corcoran M; Martin P
Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.
Zhang H; Sheng J; Ko JH; Zheng C; Zhou W; Priess P; Lin W; Novick S
J Clin Pharmacol; 2015 Apr; 55(4):401-8. PubMed ID: 25418605
[TBL] [Abstract][Full Text] [Related]
40. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.
Goldberg MR; Wong SL; Shaw JP; Kitt MM; Barriere SL
Pharmacotherapy; 2010 Jan; 30(1):35-42. PubMed ID: 20030471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
